Co-existent chronic lymphatic leukaemia with polycythaemia vera.
نویسندگان
چکیده
A patient presenting with chronic lymphocytic leukaemia and iron deficiency anaemia who, following oral iron therapy, developed the clinical and pathological features of polycythaemia vera is reported. The relationship between these two diseases when co-existing is discussed.
منابع مشابه
A patient with polycythaemia vera associated with membranoproliferative glomerulonephritis.
Myeloproliferative disorders (MPDs) are clonal disorders of the haematopoietic stem cells. These are classified as polycythaemia vera (PV), essential thrombocythaemia (ET), chronic myeloid leukaemia (CML) and myelofibrosis (MF) depending on the main haematopoietic lineage involved. Glomerulonephritis (GN) refers to a pattern of glomerular injury based on characteristic histopathology findings. ...
متن کاملPolycythaemia rubra vera and hairy cell leukaemia in the same patient: studies on the spleen.
The first association of polycythaemia rubra vera (PRV) and hairy cell leukaemia (HCL) is reported. The secretion by spleen cells in short term culture of IfGlambda to the exclusion kappa demonstrated that despite aberrant surface marker studies the HCL was a monoclonal tumour of B cells. Chromosomal studies on splenic cells were not able to demonstrate the common clonal origin of the two tumours.
متن کاملSea blue histiocytosis: a common abnormality of the bone marrow in myelodysplastic syndromes.
AIMS To determine whether myelodysplastic syndromes (MDS) are associated with sea blue histiocytosis in the bone marrow. METHODS A retrospective review of bone marrow aspirates from 35 patients presenting consecutively with MDS and from 20 patients with each of the following: normal marrow appearance (routine staging for non-Hodgkin's lymphoma), polycythaemia rubra vera, immune thrombocytopen...
متن کامل32P in the treatment of myeloproliferative disorders
UNLABELLED (32)P has been available for the treatment of myeloproliferative neoplasms (MPNs) for over seventy years. It was first used in 1938 by John H Lawrence in the treatment of polycythaemia and chronic leukaemias. With the introduction of agents such as hydroxycarbamide, interferon and anagrelide the role of (32)P has been diminished. Today, Polycythaemia Rubra Vera (PRV) and Essential Th...
متن کاملThe treatment of polycythaemia vera: an update in the JAK2 era
The clinical course of polycythaemia vera is marked by a high incidence of thrombotic complications, which represent the main cause of morbidity and mortality. Major predictors of vascular events are increasing age and previous thrombosis. Myelosuppressive drugs can reduce the rate of thrombosis, but there is concern that their use raises the risk of transformation into acute leukaemia. To tack...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Postgraduate medical journal
دوره 53 618 شماره
صفحات -
تاریخ انتشار 1977